ALLOGENE THERAPEUTICS, INC.

(ALLO)
  Report
Delayed Nasdaq  -  05/25 04:00:00 pm EDT
7.360 USD   +0.27%
05/24Goldman Sachs Adjusts Allogene Therapeutics' Price Target to $9 from $12, Keeps Neutral Rating
MT
05/19Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
GL
05/19Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société ALLOGENE THERAPEUTICS, INC.
05/19Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Imp..
GL
05/19Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Imp..
AQ
05/10Allogene Therapeutics Named 2022 Bay Area 'Best Place to Work' by San Francisco Busines..
AQ
05/09Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Franc..
GL
05/04ALLOGENE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
05/04ALLOGENE THERAPEUTICS : Q1 Earnings Snapshot
AQ
05/04ALLOGENE THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
05/04Allogene Therapeutics Reports First Quarter 2022 Financial Results
GL
05/04Allogene Therapeutics Reports First Quarter 2022 Financial Results
AQ
04/28Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First Turb..
AQ
04/28Allogene Therapeutics Appoints Susan Lundeen as Chief People Officer
GL
04/27Allogene Therapeutics to Report First Quarter 2022 Financial Results on May 4, 2022
AQ
04/27Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First Turb..
AQ
04/25ALLOGENE THERAPEUTICS : ALLO April 2022 Corporate Presentation
PU
04/14Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T Candidate Ta..
AQ
04/14Allogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility ..
AQ
04/13Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T™ Candi..
AQ
04/12Allogene Therapeutics Announces Participation in Seven Upcoming Investor Conferences
AQ
03/24Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of Hea..
AQ
03/23Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of Hea..
AQ
03/10Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Can..
GL
03/01Allogene Therapeutics Publishes Inaugural Environmental, Social and Governance (ESG) Re..
GL
02/24Allogene Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and P..
AQ
02/23ALLOGENE THERAPEUTICS : ALLO February 2022 Corporate Presentation
PU
02/23ALLOGENE THERAPEUTICS : Reports Fourth Quarter and Full Year 2021 Financial Results and Pr..
PU
02/23ALLOGENE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
02/23ALLOGENE THERAPEUTICS : Q4 Earnings Snapshot
AQ
02/23Allogene Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and P..
GL
02/16Allogene Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results on F..
GL
02/11Cellectis' Licensed Partner, Allogene Therapeutics Announces Removal of FDA Clinical Ho..
AQ
02/08ALLOGENE THERAPEUTICS : ALLO January 2022 Corporate Presentation
PU
01/26Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Confere..
GL
01/18Cellectis' Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical H..
AQ
01/12Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement wi..
AQ
01/11ALLOGENE THERAPEUTICS : JPM Presentation 2022
PU
01/11Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T Clini..
AQ
01/11Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement wi..
AQ
01/11Cellectis' Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical ..
AQ
01/10Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T&trade..
AQ
01/04Allogene Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conf..
AQ
2021ALLOGENE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Events (fo..
AQ
2021Allogene Therapeutics Expands Headquarters to Support Company Growth and Pipeline Innov..
AQ
2021Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgki..
AQ
2021Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single D..
AQ
2021ALLOGENE THERAPEUTICS : ASH 2021 Conference Call Presentation
PU
2021Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single D..
AQ
2021Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgki..
AQ
2021Allogene Therapeutics Announces Conference Call to Review ALPHA, ALPHA2 and UNIVERSAL P..
GL
2021ALLOGENE THERAPEUTICS : Corporate Presentation - November 2021
PU
2021Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Confere..
GL
2021Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Confere..
GL
2021Allogene Therapeutics to Showcase Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL Al..
AQ
2021Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update ..
PU
2021ALLOGENE THERAPEUTICS : Q3 Earnings Snapshot
AQ
2021ALLOGENE THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
2021Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update ..
AQ
2021Allogene Therapeutics to Showcase Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL Al..
AQ
2021SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allog..
PR
2021Allogene Therapeutics to Report Third Quarter Financial Results on November 4, 2021
GL
2021SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allog..
PR
2021Occidental Petroleum, Chubb rise; Allogene, Oshkosh fall
AQ
2021ALLOGENE THERAPEUTICS : Reports FDA Clinical Hold of AlloCAR T Trials Based on a Single Pa..
AQ
2021ALLOGENE THERAPEUTICS, INC. : Other Events (form 8-K)
AQ
2021ALLOGENE THERAPEUTICS : Reports FDA Clinical Hold of AlloCAR T Trials Based on a Single Pa..
GL
2021ALLOGENE THERAPEUTICS : Adds Renowned CAR T Expert, Jae Park, M.D. to its Scientific Advis..
AQ
2021Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferen..
GL
2021ALLOGENE THERAPEUTICS : Corporate Presentation - August 2021
PU
2021ALLOGENE THERAPEUTICS : Receives FDA Orphan Drug Designation (ODD) for ALLO-715 for the Tr..
AQ
2021ALLOGENE THERAPEUTICS : Reports Second Quarter 2021 Financial Results (Form 8-K)
PU
2021ALLOGENE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Re..
AQ
2021ALLOGENE THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
2021ALLOGENE THERAPEUTICS : Q2 Earnings Snapshot
AQ
2021ALLOGENE THERAPEUTICS : Reports Second Quarter 2021 Financial Results
AQ
2021ALLOGENE THERAPEUTICS : Appoints Industry Leaders Elizabeth Barrett and Vicki Sato Ph.D. t..
AQ
2021ALLOGENE THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
1  2  3Next
Upcoming event on ALLOGENE THERAPEUTICS, INC.